Loading...
•
Dec 31, 2022
Annexon Q4 2022 Earnings Report
Annexon reported fourth quarter and year-end 2022 financial results and reiterated anticipated milestones.
Key Takeaways
Annexon reported a net loss of $34.4 million for the quarter ended December 31, 2022, and cash and cash equivalents and short-term investments were $242.7 million as of December 31, 2022.
Initiated dosing in Phase 1 Multiple-Ascending Dose (MAD) Trial of ANX1502.
Completed expanded enrollment in the ongoing pivotal Phase 3 trial of ANX005 in patients with Guillain-Barré syndrome (GBS) in 2023 with pivotal data anticipated in the first half of 2024.
Completed the ongoing SAD trial of ANX1502 and identify the maximum tolerated dose; execute the ongoing MAD trial in healthy volunteers; and initiate a proof-of-concept study in patients with cold agglutinin disease (CAD) in 2023.
Completed the ongoing Phase 2 trial of ANX007 in patients with geographic atrophy (GA) and report initial data in mid-2023 followed by additional data by the end of 2023 after the conclusion of the six-month off-treatment period.
Annexon
Annexon
Forward Guidance
Annexon expects its cash, cash equivalents and marketable securities as of December 31, 2022, to be sufficient to fund the company’s current operating plan into 2025.